Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Nifedipine
Chiesi Ltd
C08CA05
Nifedipine
30mg
Modified-release tablet
Oral
No Controlled Drug Status
Caution - AMP level prescribing advised
BNF: 02060200; GTIN: 5028613001905
0108006100/01 PACKAGE LEAFLET: INFORMATION FOR THE USER ADIPINE ® XL 30 MG & 60 MG PROLONGED RELEASE TABLETS Nifedipine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. WHAT ADIPINE IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ADIPINE 3. HOW TO TAKE ADIPINE 4. POSSIBLE SIDE EFFECTS 5. HOW TO STORE ADIPINE 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT ADIPINE IS AND WHAT IT IS USED FOR Adipine XL Prolonged Release Tablets contain nifedipine which belongs to a group of medicines called calcium- channel blockers that act on the cardiovascular system (the heart and blood vessels). Adipine XL is used to treat high blood pressure or angina (chest pain). They are called prolonged release tablets because they are manufactured in a way that allows the nifedipine to be released and slowly absorbed by your body over a period of several hours. For high blood pressure: Adipine XL works by relaxing and expanding the blood vessels. This makes the blood flow more easily and lowers blood pressure. Lower blood pressure reduces the strain on your heart. For angina: Adipine XL works by relaxing and expanding the arteries supplying the heart. This allows more blood and oxygen to reach the heart and decreases the strain on it. Your angina attacks will be less severe and less frequent if there is less strain on the heart. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ADIPINE DO NOT TAKE ADIPINE: • if you are allergic to nifedipine, other calcium-channel blockers (e.g verapamil, diltiazem or fel Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Adipine XL 30 mg Tablets Adipine XL 60 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adipine XL 30mg Tablets Each tablet contains 30mg of nifedipine Adipine XL 60mg Tablets Each tablet contains 60mg of nifedipine 3 PHARMACEUTICAL FORM Adipine XL 30mg Tablets Prolonged release tablet Each pale red tablet is round and biconvex and embossed with "30" on one side. Adipine XL 60mg Tablets Prolonged release tablet Each pale red tablet is round and biconvex and embossed with "60" on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The tablets are indicated for : - the treatment of all grades of hypertension - the prophylaxis of chronic stable angina pectoris, either as monotherapy or in combination with a beta-blocker 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology In mild to moderate hypertension, the recommended initial dose is one 20 mg tablet once-daily. In severe hypertension, the recommended initial dose is one 30 mg tablet once-daily. If necessary, the dosage can be increased according to individual requirements up to a maximum of 90 mg once-daily. For the prophylaxis of angina pectoris, the recommended initial dose is one 30 mg tablet once-daily. The dosage can be increased according to individual requirements up to a maximum of 90 mg once-daily. Prophylactic antianginal efficacy is maintained when patients are switched from other calcium antagonists such as diltiazem or verapamil to Adipine XL. Patients switched from other calcium antagonists should initiate therapy at the recommended initial dose of 30 mg Adipine XL once-daily. Subsequent titration to a higher dose may be initiated as warranted clinically. Co-administration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all (see section 4.5). _Duration of treatment_ Treatment may be continued indefinitely. _ _ _Additional information on special populations _ _Paediatric population _ Th Read the complete document